Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
Carfilzomib (Kyprolis®, Amgen), a second-generation proteasome inhibitor, is capable of covalent bonding and irreversible inhibition of the 20S proteasome chymotrypsin-like activity. In 2016 this drug was approved in Russia for monotherapy of relapsed refractory multiple myeloma (MM) and in combinat...
Furkejuvvon:
| Váldodahkkit: | , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Russo |
| Almmustuhtton: |
Practical Medicine Publishing House
2019-01-01
|
| Ráidu: | Клиническая онкогематология |
| Fáttát: | |
| Liŋkkat: | https://bloodjournal.ru/index.php/coh/article/view/290 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|